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Background: Bypass graft disease is related to proliferation and migration of
vascular smooth muscle cells and to platelet activation with thrombus formation.
Nitric oxide inhibits these biological responses; it has never been demonstrated,
however, whether this occurs in intact human vascular tissue after endothelial nitric
oxide synthase gene transfer.
Methods: We examined whether endothelial nitric oxide synthase overexpression
inhibits biological features of bypass graft disease in saphenous vein tissue.
Results: The nitric oxide donor diethylenetriamineNONOate inhibited proliferation
(P  .001) and migration (P  .001) of human saphenous vein vascular smooth
muscle cells in response to 20% serum in a concentration-dependent manner. A
similar effect on proliferation (P  .05) and migration (P  .05) without any
cytotoxicity was observed after adenoviral endothelial nitric oxide synthase trans-
fection. Staining of saphenous vein tissue for placental alkaline phosphatase dem-
onstrated that adenoviral transfection was efficient. Consistent with this observation,
endothelial nitric oxide synthase protein expression and nitric oxide release were
enhanced in transfected tissue. Further, endothelial nitric oxide synthase overex-
pression inhibited vascular smooth muscle cell outgrowth from saphenous vein
explants over 21 days; 48%  12% of explants exhibited outgrowth after treatment
with endothelial nitric oxide synthase adenovirus as compared with 69%  10% in
those infected with control adenovirus and 90%  5% in uninfected tissue (P 
.05). Similarly, platelet adhesion to human saphenous vein tissue was inhibited by
endothelial nitric oxide synthase overexpression; adhesion was reduced in segments
infected with endothelial nitric oxide synthase adenovirus (58% 6%) as compared
with those infected with control adenovirus (107%  8%) or uninfected saphenous
vein (100%; P  .05).
Conclusions: These data demonstrate that endothelial nitric oxide synthase gene
transfer inhibits biological features of bypass graft disease in intact human saphe-
nous vein tissue. Therefore, endothelial nitric oxide synthase transfection represents
a promising gene transfer approach to prevent venous bypass graft disease.
oronary artery disease is the most common cause of morbidity and
mortality in Western countries.1 Treatment options include drugs,
balloon angioplasty, and coronary artery bypass graft surgery.
Coronary artery bypass graft surgery reduces both symptoms and
mortality, particularly in patients with severe disease.2 It is per-
formed with arterial grafts (most commonly the internal thoracic
artery) or venous conduits (the saphenous vein; SV).
Whereas internal thoracic
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artery grafts have excellent long-term patency, SV grafts are
prone to early thrombotic occlusion and, within several
years after implantation, to bypass graft disease.3 Acute
thrombotic occlusion of SV grafts occurs less frequently
since the introduction of platelet inhibitors for treating these
patients.4 Bypass graft disease, however, remains a signif-
icant clinical problem, because approximately half of the
venous grafts occlude within 10 years.5
The mechanisms of bypass graft disease include (1)
proliferation and migration of vascular smooth muscle cells
(VSMC), leading to neointima formation and vascular re-
modeling, and (2) platelet activation with thrombus forma-
tion.6 Because veins are not well adapted to the arterial
circulation, which is characterized by high pressure and
pulsatile flow, a promising strategy for the prevention of
bypass graft disease consists of modifying the biological
properties of the vessel by gene transfer. A candidate gene
in this context is endothelial nitric oxide synthase (eNOS),
because SVs exhibit a lower expression of eNOS, a reduced
basal release of nitric oxide (NO), and less pronounced
endothelium-dependent relaxation as compared with arter-
ies.7 In contrast to eNOS, the inducible isoform of nitric
oxide synthase (NOS) is upregulated in SV bypass grafts
and may delay the development of graft disease.8 Indeed,
NO not only is a vasodilator, but also inhibits platelet
aggregation, as well as the proliferation and migration of
cultured VSMC.9 Therefore, we investigated whether eNOS
overexpression inhibits these processes in human SV tissue
segments.
Methods
Recombinant Adenovirus
An adenoviral vector for expression of human placental alkaline
phosphatase (AdhpAP) and a control virus without transgene
(AdE1) were derived from Ad5 sub360 and prepared as previ-
ously described.10 A similar virus for expression of endothelial
NOS (AdeNOS) and the respective control virus were provided by
Dr Stefan Janssens, Leuven, Belgium. These viruses were derived
from Ad5 dL309 and were thus slightly different from Ad5
sub360.11 However, comparison of the effect of both control
viruses on VSMC proliferation did not show any difference (n 
5; data not shown). Therefore, for the sake of clarity, both control
viruses are called AdE1. The titer of purified viruses was deter-
mined by plaque assay on 293 cells by using an adsorption time of
24 hours and counting the number of plaques on day 12 after
infection.12 Viral titers ranged from 2  1010 to 2  1011 pfu/mL
for all preparations. The titer of wild-type virus in the purified
preparations was determined by plaque assay on A549 cells by
using the same conditions and was 1 in 109 pfu/mL for all
preparations.
Cell Culture, Tissue Culture, and Explant Preparation
SV segments were obtained from human donors undergoing cor-
onary bypass surgery through institutional consent. Vascular ex-
plants were prepared as previously described.13 Outgrowth of
VSMC from explants was observed for 21 days. For isolation of
VSMC, explants were trypsinized, the cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) with 20% fetal
calf serum (FCS; Gibco BRL, Life Technologies, Inc, Rockville,
Md), characterized by immunofluorescent staining for smooth
muscle -actin, and used between passage 2 and 1013; 293 cells
and A549 cells were obtained from the American Type Culture
Collection (Manassas, Va) and cultured as recommended.
Transfection
VSMC were transfected at a multiplicity of infection of 1000 pfu
per cell; this resulted in 99% transfected cells (n  4; data not
shown). Cytotoxicity was assessed by trypan blue staining as
previously described.14 Tissue segments were incubated with a
viral titer of 1  109 pfu/mL for 2 hours at 37°C and then kept in
DMEM with 20% FCS for an additional 48 hours. Immunohisto-
chemical staining for von Willebrand factor revealed that the
endothelial layer was not fully maintained in the isolated SV tissue
under control conditions, and this is consistent with published
observations.15 However, transfection and incubation did not af-
fect the morphologic integrity of the remaining endothelial layer (n
 4; data not shown). Transfection efficiency was analyzed by
using AdhpAP and determined by staining with NBT/BCIP (ni-
troblue tetrazolium chloride/5-bromo-4-chloro-3-indolylphosphate
p-toluidine; Invitrogen) as previously described.16 Stained tissue
segments were observed under a stereo microscope (Wild Leitz,
Heerbrugg, Switzerland) at a magnification of 30.
Proliferation
VSMC were seeded at a density of 10,000 cells per 35-mm dish
and cultured for 24 hours, resulting in random proliferation at the
beginning of treatment. The cells were treated with the NO donor
diethylenetriamineNONOate (DETANO; 105 to 103 mol/L;
Alexis, La¨ufelfingen, Switzerland) because it has a half-life of 27
hours and releases NO according to first-order kinetics.14 The cells
were maintained in DMEM with 20% FCS, media were changed
every day, and fresh DETANO was added after every media
change. Cell number was determined every other day for up to 4
days by using a hematocytometer. An analogous protocol was used
for transfected VSMC, which were maintained in normal media
containing 20% FCS for 48 hours after transfection. Cell-cycle
distribution was determined by propidium iodide staining and
fluorescence-activated cell sorting analysis as previously de-
scribed.14
Migration
VSMC were seeded at a density of 250,000 cells per 150-mm dish
and cultured for 24 hours before DETANO treatment. The cells
were maintained in DMEM with 20% FCS for 48 hours, media
were changed every day, and fresh DETANO was added after
every media change. The cells were harvested for analysis of
migration in response to 20% FCS in the presence of DETANO in
a 2-chamber system (Neuroprobe Inc., Cabin John, Md) as previ-
ously described.17 The number of migrated cells was determined
by staining (Diff-Quik; Dade Diagnostics Inc., Aguada, Puerto
Rico) and counting the cells at 400 magnification on 4 random
microscopic fields per group.17 An analogous protocol was used
for transfected VSMC, which were maintained in normal media
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containing 20% FCS for 48 hours after transfection. Cell attach-
ment was assessed by seeding 40,000 cells and determining the
number of cells sticking to the culture dish after an incubation time
of 5 hours.18
Platelet Adherence
Venous blood was obtained from healthy human donors who had
not taken any medication within the last 10 days. Platelets were
collected as previously described except for the final washing
solution, which contained 0.15 mol/L NaCl, 1 mmol/L ethyl-
enediaminetetraacetic acid, and 0.01 mol/L HEPES (EHS buffer;
pH 7.6).19 Washed platelets were equilibrated in EHS buffer at
4°C for 10 minutes, sodium periodate was added to the final 1
mmol/L, and platelets were centrifuged at 800g and resuspended in
EHS buffer at a concentration of 2.5  108/mL. [3H]Sodium
borohydride 0.1 mCi was added and incubated for 5 minutes.
Labeled platelets were centrifuged, washed 3 times, and resus-
pended in EHS buffer containing 1% FCS. SV segments were
opened longitudinally, fixed with the intimal face up, and incu-
bated with labeled platelets (2.5  108/mL) for 30 minutes. After
washout, the number of adhering platelets was determined by
using a beta counter.
Western Blot Analysis
Western blot analysis was performed on whole-cell lysates as
previously described.20 A total of 60 g of protein was loaded per
lane, resolved by sodium dodecyl sulfate–polyacrylamide gel elec-
trophoresis under reducing conditions, blotted onto polyvinylidene
difluoride membranes, and analyzed by chemiluminescence (Am-
ersham, Piscataway, NJ). Equal loading of proteins was controlled
for by staining with Ponceau S.
NO Release
After transfection, tissue pieces were kept in DMEM with 20%
FCS at 37°C for 48 hours. NO release was stimulated by 105
mol/L calcium ionophore A23187, a concentration that fully acti-
vates eNOS. NO was measured by a porphyrinic microsensor as
previously described.21
Statistics
Results represent the mean value of 5 experiments as indicated in
the text. Data are expressed as mean  SEM, and statistical
comparisons were performed by using Student t tests for unpaired
observations or analysis of variance with Dunnett t-test correction
whenever appropriate.
Results
Proliferation
DETANO inhibited VSMC proliferation in response to 20%
FCS in a concentration-dependent manner. FCS increased
the cell number over 4 days from 20.859  103  1.336 
103 to 165.406  103  27.649  103. DETANO reduced
this effect to 130.125 103 23.029 103 at 105 mol/L,
37.703  103  3.078  103 at 104 mol/L, and 5.750 
103  0.793  103 at 103 mol/L (P  .001 vs control;
Figure 1, A). Adenoviral transfection of eNOS complemen-
tary DNA (cDNA) inhibited VSMC proliferation in re-
sponse to 20% FCS. FCS increased the cell number over 2
days from 14.625  103  1.102  103 to 45.694  103 
7.070  103 under control conditions as compared with
34.938  103  3.038  103 with the control adenovirus
(AdE1; P  .32 vs control) and 22.831  103  1.921 
103 with the NOS adenovirus (AdeNOS; P  .05 vs control
and P .05 vs AdE1; Figure 1, B). Trypan blue exclusion
was identical in transfected versus control VSMC (control:
1.35%  0.88% trypan blue–positive cells; AdE1: 1.57%
 1.02%; AdeNOS: 1.57%  0.92%; n  4; P  .56).
Thus, no toxic effect of AdeNOS was involved. Consistent
Figure 1. A, Effect of the NO donor diethylenetriamineNONOate
(DETANO) on proliferation of human saphenous vein vascular
smooth muscle cells (VSMC) to 20% fetal calf serum (FCS): FCS
increased the cell number within 4 days from 20.859  103 
1.336  103 to 165.406  103  27.649  103; DETANO reduced it
to 130.125 103 23.029 103 (105 mol/L), 37.703 103 3.078
 103 (104 mol/L), and 5.750  103  0.793  103 (103 mol/L; P
< .001). B, Effect of endothelial nitric oxide synthase (eNOS)
overexpression on proliferation of human saphenous vein VSMC
to 20% FCS: FCS increased the cell number within 4 days from
14.625  103  1.102  103 to 45.694  103  7.070  103 under
control conditions, 34.938  103  3.038  103 with control
adenovirus (AdE1), and 22.831  103  1.921  103 with NOS
adenovirus (AdeNOS; P < .05 vs control).
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with this observation, a shift in cell-cycle distribution oc-
curred after eNOS transfection (control, 75% of cells in
G0/G1 phase; AdE1, 76%; and AdeNOS, 81%; n  4).
Migration
DETANO inhibited VSMC migration in response to 20%
FCS in a concentration-dependent manner. FCS increased
the number of migrated cells within 5 hours from 4.8  2.7
to 26.4  2.1. DETANO reduced this effect to 20.8  2.2
at 105 mol/L, 14.0  1.6 at 104 mol/L, and 9.6  1.4 at
103 mol/L (P  .001 vs control; Figure 2, A). Adenoviral
transfection of eNOS cDNA inhibited VSMC migration in
response to 20% FCS. FCS increased the number of mi-
grated cells within 5 hours from 4.5  1.8 to 60.3  6.0
under control conditions as compared with 46.3  6.0 with
the control adenovirus (AdE1; P  .48 vs control) and
35.5  6.0 with the NOS adenovirus (AdeNOS; P  .05 vs
control and P  .27 vs AdE1; Figure 2, B). Cell attach-
ment was not affected by eNOS transfection (control:
20.031  103  0.890  103 attached cells per 6-well dish;
AdE1: 20.344  103  0.756  103; AdeNOS: 19.344 
103  0.790  103; P  .71).
NO Release
Adenoviral transfection of human SV was assessed by over-
expression of human placental alkaline phosphatase
(hpAP). NBT/BCIP staining revealed the presence of func-
tional hpAP in SV transfected with hpAP adenovirus (Adh-
pAP), but not with control adenovirus (AdE1) or in
transinfected vessels (Figure 3, A). Expression of eNOS in
human SV after adenoviral transfection was examined by
Western blot analysis and demonstrated the presence of
eNOS protein in SV transfected with eNOS adenovirus
(AdeNOS), but not with control adenovirus (AdE1) or in
untransfected vessels (Figure 3, B). NO release of human
SV on stimulation with the calcium ionophore A23187
reached 339%  74% of control after eNOS transfection,
whereas it was 65%  13% of control after treatment with
AdE1 (P  .01 for control vs AdeNOS; P  .005 for
AdE1 vs AdeNOS; P  .22 for control vs AdE1). Thus,
NO release increased approximately 3-fold after eNOS
transfection as compared with control conditions (Figure 3,
C).
Explant Outgrowth
The effect of eNOS overexpression on explant outgrowth
from human SV was determined for an observation period
of 21 days. A total of 90%  5% of explants exhibited
outgrowth of VSMC in uninfected SV as compared with
69%  10% in those transfected with control adenovirus
(AdE1) and 47%  12% in those transfected with eNOS
adenovirus (AdeNOS; P  .05 vs control; Figure 4, A).
Platelet Adherence
The effect of eNOS overexpression on platelet adherence to
human SV was analyzed with 3H-labeled platelets and SV
segments in organ culture. Platelet adherence was reduced
in SV transfected with AdeNOS (58%  6%) as compared
with those transfected with control adenovirus (AdE1;
107%  8%) or untransfected SV (100%; P  .05 vs
control; Figure 4, B). The effect of eNOS transfection on
platelet adherence was inhibited by the competitive inhibi-
tor of eNOS, N-nitro-L-arginine methyl ester (90%  3%).
Figure 2. A, Effect of the NO donor diethylenetriamineNONOate
(DETANO) on migration of human saphenous vein vascular
smooth muscle cells (VSMC) to 20% fetal calf serum (FCS): FCS
increased the migrating cell number within 5 hours from 4.8 2.7
to 26.4  2.1; DETANO reduced it to 20.8  2.2 (105 mol/L), 14.0
 1.6 (104 mol/L), and 9.6  1.4 (103 mol/L; P < .001). B, Effect
of endothelial nitric oxide synthase (eNOS) overexpression on
migration of human saphenous vein VSMC to 20% FCS: FCS
increased the migrating cell number within 5 hours from 4.5 1.8
to 60.3  6.0 under control conditions, 46.3  6.0 with control
adenovirus (AdE1), and 35.5  6.0 with NOS adenovirus (Ad-
eNOS; P < .05 vs control).
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Discussion
This study demonstrates that ex vivo eNOS gene transfer
inhibits the biological features of bypass graft disease in
intact human SV tissue segments. Indeed, adenoviral trans-
fection of eNOS inhibited proliferation and migration of
human SV VSMC, impaired VSMC outgrowth from SV
explants, and reduced platelet adherence to SV segments.
Hence, this study confirms and expands previous reports on
transfection of human SV.22-24
The control adenovirus had some effect on the prolifer-
ation and migration of VSMC. Similar to our previous
observations, a toxic effect leading to cell death is unlikely
because trypan blue staining did not differ from control
conditions.14 Further, an effect of the virus on expression of
eNOS or inducible NOS can be excluded, because the
control vector did not have any effect on NO formation as
determined by the porphyrinic microsensor. However, even
though cell death was not induced, it cannot be excluded
that the nonspecific action of the virus may result in some
degree of inflammation after the grafts are placed in the
circulation.
In the first several months after coronary bypass graft
operation, graft occlusion is related to thrombus formation
Figure 3. A, Expression of human placental alkaline phosphatase
(hPAP) in human saphenous vein (SV) after adenoviral transfec-
tion: NBT/BCIP staining shows functional hPAP in SV transfected
with hPAP adenovirus (AdhpAP), but not with control adenovirus
(AdE1) or in untransfected vessels. B, Expression of endothelial
nitric oxide synthase (eNOS) in human SV after adenoviral trans-
fection: Western blot analysis shows eNOS protein in SV trans-
fected with eNOS adenovirus (AdeNOS), but not with control
adenovirus (AdE1) or in untransfected vessels. C, Release of NO
from human SV after adenoviral transfection: direct NO measure-
ment by porphyrinic microsensor revealed a threefold increase in
NO release after transfection with eNOS adenovirus (AdeNOS) as
compared with control adenovirus (AdE1) or untransfected ves-
sels. Left panel, original recording; right panel, average values
from 4 independent experiments (P < .01 for eNOS vs control).
Figure 4. A, Effect of endothelial nitric oxide synthase (eNOS)
overexpression on explant outgrowth from human saphenous
vein (SV): after 21 days, 90% of explants exhibited outgrowth of
vascular smooth muscle cells in untransfected SV as compared
with 69% in those transfected with control adenovirus (AdE1)
and 48% with eNOS adenovirus (AdeNOS; P < .05 vs control). B,
Effect of eNOS overexpression on platelet adhesion to human SV:
platelet adhesion was reduced in SV transfected with eNOS
adenovirus (AdeNOS; 57%) as compared with those transfected
with control adenovirus (AdE1; 107%) or untransfected SV
(100%; P < .05 vs AdeNOS).
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that is due to vein graft injury and associated coronary
artery disease with low blood flow in the vein graft.25-27 The
low release of NO from SV endothelium on platelet aggre-
gation may primarily be responsible for this high incidence
of thrombotic events. Platelet deposition in vein grafts starts
during surgery as soon as blood flow through the graft is
initiated.26 Thus, antithrombotic therapy with platelet-inhib-
itory drugs is started perioperatively and indeed reduces the
rate of early graft occlusion, albeit without preventing it.27
Because eNOS overexpression in SV tissue results in re-
duced platelet adhesion because of NO release, such a
transfection would reduce the incidence of thrombotic
events early after bypass graft implantation. However, gene
expression requires several hours to reach a high level of
recombinant protein in transfected cells; indeed, in vivo
experiments revealed that maximal gene expression in a
vessel occurs a few days after adenoviral transfection and
declines to a low level within 3 or 4 weeks.28 Endothelial
NOS overexpression would therefore certainly not replace
platelet-inhibitory drugs perioperatively, but it may be com-
bined with the latter in an effective manner, resulting in
improved patency rates. Indeed, thrombotic occlusion of
venous grafts still remains a significant clinical problem for
several months after bypass.29
Platelet deposits, through the release of potent growth
factors such as platelet-derived growth factor, contribute
importantly to VSMC proliferation and migration and, in
turn, graft stenosis. Thus, eNOS overexpression may have a
beneficial effect on neointima formation in venous bypass
grafts, because transfection of SV tissue with eNOS cDNA
resulted in reduced platelet adhesion. Moreover, eNOS
overexpression is likely to reduce neointima formation by a
direct inhibitory effect on this phenomenon as well, because
both proliferation and migration of SV VSMC, as well as
SV explant outgrowth, were reduced under these conditions.
Consistent with a specific inhibition of cell-cycle progres-
sion, eNOS transfection did not have any toxic effect on SV
VSMC but induced a shift in cell-cycle distribution toward
G1 phase. Indeed, NO inhibits VSMC proliferation by spe-
cifically changing the expression and activity of cell-cycle
regulatory proteins leading to G1 phase arrest.14 The inhib-
itory effect of eNOS transfection on migration was specific
as well, because VSMC attachment was not affected. The
inhibition of migration may be related to altered functioning
of integrins or metalloproteinases.30 With currently avail-
able vectors, adenoviral transfection results in high expres-
sion levels, which are, however, maintained for only a few
weeks; therefore, a pronounced and maintained effect on
late graft occlusion cannot be expected with these vectors.
However, these data may serve as proof of concept. More-
over, because neointima formation in venous bypass grafts
is induced by platelet aggregation, with the release of cy-
tokines promoting proliferation and migration of VSMC,
the platelet-inhibitory effect of recombinant eNOS may still
prove beneficial for late occlusion. Indeed, prevention of
acute thrombosis in vein grafts markedly reduces subse-
quent neointima formation several months after operation.
Moreover, new vectors may prove superior, once the prin-
ciple of eNOS gene transfer is established by using such
early-generation vectors.
Thus, adenoviral transfection of eNOS cDNA into hu-
man SV tissue ex vivo is effective and inhibits the biolog-
ical features of bypass graft disease in the isolated tissue.
Local overexpression of this gene may prove beneficial for
both early and late graft occlusion, especially in combina-
tion with platelet-inhibitory drugs. This study indicates that
clinical studies with transfection of eNOS cDNA for pre-
venting human bypass graft disease should be performed in
patients.
The adenovirus for expression of endothelial NOS (AdeNOS)
and the respective control virus were provided by Dr Stefan
Janssens, Leuven, Belgium.
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